Aspire Biopharma Holdings, Inc.

8-K Other events Jul 20, 2026 8-K Shareholder vote results Jun 22, 2026 8-K Other events Jun 12, 2026 8-K Entered a material agreement; Regulation FD disclosure Jun 12, 2026 10-Q Quarter ended 2026-03-31 May 15, 2026 8-K Amended charter or bylaws May 14, 2026 8-K Regulation FD disclosure Apr 20, 2026 8-K/A Entered a material agreement; Amended charter or bylaws Apr 17, 2026 8-K Entered a material agreement; Amended charter or bylaws Apr 16, 2026 8-K Shareholder vote results Apr 16, 2026 8-K Regulation FD disclosure Apr 16, 2026 8-K Entered a material agreement Apr 15, 2026 10-K/A Fiscal year ended 2025-12-31 Apr 8, 2026 10-K Fiscal year ended 2025-12-31 Mar 30, 2026 8-K Entered a material agreement; Unregistered sale of equity; Director or officer change; Regulation FD disclosure Feb 12, 2026 8-K Amended charter or bylaws Feb 6, 2026 8-K Entered a material agreement; Unregistered sale of equity Jan 30, 2026 8-K Director or officer change Jan 15, 2026 8-K Director or officer change Jan 13, 2026 8-K Entered a material agreement; Unregistered sale of equity Jan 6, 2026 10-Q/A Quarter ended 2025-09-30 Nov 14, 2025 10-Q Quarter ended 2025-09-30 Nov 14, 2025 8-K Entered a material agreement; Terminated a material agreement; Took on a direct financial obligation; Unregistered sale of equity Nov 14, 2025 8-K Shareholder vote results Nov 5, 2025 8-K Delisting notice or listing-rule failure Oct 17, 2025 8-K Unregistered sale of equity; Changed accountants Sep 26, 2025 8-K Entered a material agreement Aug 22, 2025 10-Q Quarter ended 2025-06-30 Aug 13, 2025 10-Q/A Quarter ended 2025-03-31 Aug 13, 2025 8-K Director or officer change Jul 30, 2025 8-K Other events Jun 18, 2025 8-K Director or officer change; Regulation FD disclosure Jun 10, 2025 10-Q Quarter ended 2025-03-31 May 14, 2025 8-K Entered a material agreement Apr 30, 2025 8-K Delisting notice or listing-rule failure Apr 18, 2025 10-K Fiscal year ended 2024-12-31 Apr 7, 2025 8-K Entered a material agreement; Completed an acquisition or disposition; Took on a direct financial obligation; Unregistered sale of equity; Modified rights of security holders; Changed accountants; Change in control; Director or officer change; Amended charter or bylaws; Item 5.05; Item 5.06; Regulation FD disclosure Feb 21, 2025 8-K Entered a material agreement; Took on a direct financial obligation; Unregistered sale of equity; Regulation FD disclosure Feb 20, 2025 8-K Shareholder vote results; Other events Feb 10, 2025 8-K Entered a material agreement; Unregistered sale of equity Dec 26, 2024